Adenocarcinoma of the Esophagus Terminated Phase 2 Trials for Panitumumab (DB01269)

IndicationStatusPhase
DBCOND0030040 (Adenocarcinoma of the Esophagus)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01307956Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction CancerTreatment